Connect with us

Technology

Precision Biologics to Present at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1st, 2024

Published

on

BETHESDA, Md., May 30, 2024 /PRNewswire/ — Precision Biologics, Inc. reports that novel findings from its ongoing phase 2 clinical trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy, will be presented in a poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, McCormick Place Convention Center, Chicago, Illinois, USA, June 1st, 2024.  

Poster title: Reduction of circulating naïve Tregs and gMDSCs and low levels of soluble MICA are prognostic for efficacy of combined NEO-201 and pembrolizumab

Presentation of the poster in person will be made at the McCormick Place Convention Center in Chicago, Illinois, USA, on Saturday June 1st, 2024, Hall A from 9am – 12pm, Session: Developmental Therapeutics-Immunotherapy, poster board #9, poster # 2530.

BACKGROUND:

The employment of immune checkpoint inhibitors (ICIs), such as pembrolizumab (anti-PD-1 mAb), in cancer immunotherapy has been shown to enhance activity of the immune system against cancer cells.
 Although ICIs show efficacy and improved survival of certain cancer patients, the response rate of PD-1/PD-L1 blockade against solid tumors is around 20-30% in the first line setting and significantly lower in checkpoint refractory disease. One cause identified for this low response rate is the infiltration of the tumor microenvironment (TME) by immunosuppressive cells, such as regulatory T cells (Tregs) and granulocytic myeloid-derived suppressor cells (gMDSCs). The accumulation of these immunosuppressive cells in the TME impairs the antitumor immunity triggered by ICIs.  
 A strategy to restore antitumor immunity and overcome tumor resistance to ICIs is to combine ICIs with anticancer drugs able to bind to and deplete Tregs and gMDSCs.
 NEO-201 is a humanized IgG1 monoclonal antibody that binds to Core 1 and/or extended Core 1 O-glycans expressed by several human solid and blood tumors, as well as mature granulocytes, but it does not bind to most normal tissues and human immune cell subsets (B cells, CD4+ T cells, CD8+ T cells, NK cells, monocytes). Previous studies showed that NEO-201 can bind and mediate the killing of Tregs via CDC. Further studies presented at AACR in 2023 showed that NEO-201 can bind and mediate the killing of gMDSCs via ADCC.
 The ability of NEO-201 to mediate the killing of immunosuppressive cells served as the rationale for combination of NEO-201 with pembrolizumab in the ongoing phase II clinical trial (NCT03476681) for the treatment of patients with NSCLC, head and neck, cervical and endometrial cancers who were refractory to multiple lines of standard treatment, including ICIs.
 Preliminary findings from this ongoing clinical trial presented at the CRI-ENCI-AACR in September 2023 in Milan, Italy and at the SITC annual meeting in November 2023 in San Diego, CA, USA, revealed that, after combination treatment with NEO-201 and pembrolizumab some patients experienced durable stable disease (SD). Patients with durable SD (>84 days) demonstrated a decreasing trend in circulating gMDSCs and Tregs. Conversely, patients with progressive disease (PD) exhibited an increasing trend of circulating gMDSCs and Tregs. This preliminary data suggests that elimination of circulating gMDSCs and Tregs mediated by NEO-201 may enable patients to overcome resistance to PD-1/PD-L1 checkpoint inhibitors, in subjects for whom pembrolizumab is currently indicated and with solid tumors resistant to prior ICIs treatment.

STUDY PRESENTED AT ASCO 2024:

NEO-201 uses Natural Killer (NK) cells as effector cells to mediate the killing of its target cells through ADCC. Several studies reported that cancer cells inhibit NK cell antitumor activity by releasing soluble factors into the bloodstream, such as soluble MHC class 1 chain-related protein A (MICA.) Elevated serum levels of soluble MICA (sMICA) have been correlated with impairment of NK cell activity, cancer progression and metastasis.
 This study reports that median serum levels of sMICA pre-treatment were 33-fold higher in patients with PD compared to patients with SD and that levels of sMICA remained elevated in patients with PD and low in patients with SD at all time points post treatment.
 High levels of sMICA in patients with PD can impair NK cell activity. This impairment negatively impacts the NK cell mediated ADCC triggered by NEO-201 against cancer cells, Tregs and gMDSCs. Consequently, the effectiveness of NEO-201 and pembrolizumab treatment is reduced, leading to disease progression in these patients.
 Conversely, low levels of sMICA pre- and post-treatment do not hinder the antitumoral activity of NK cells. This allows NEO-201 to effectively mediate the killing of its target cells, including cancer cells, Tregs and gMDSCs, through ADCC. As a result, this phenomenon can lead to the durable stabilization of the disease. 
 This study reports that low levels of sMICA, together with the reduction of both circulating Tregs and gMDSCs mediated by NEO-201, were associated with durable SD in cancer patients refractory to prior ICIs and that they could be favorable prognostic markers for clinical benefit following combination treatment with NEO-201 and pembrolizumab. Ongoing enrollment in this clinical trial will validate these findings in larger cohorts.

View original content:https://www.prnewswire.com/news-releases/precision-biologics-to-present-at-the-american-society-of-clinical-oncology-asco-annual-meeting-on-june-1st-2024-302158596.html

SOURCE Precision Biologics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

NCL (Formerly Natural Cure Labs) Unveils New Brand Identity, Reinforcing Its Position as a Leading Monolaurin Supplement Company

Published

on

By

Natural Cure Labs, one of the most recognized monolaurin supplement brands in the United States, is officially transitioning to NCL – the same company, same formulations, and same science-backed standards, under a streamlined name.

ST. PETERSBURG, Fla., April 25, 2026 /PRNewswire-PRWeb/ — Natural Cure Labs, one of the most recognized monolaurin supplement brands in the United States, is officially transitioning to NCL. The company, founded in 2015, is adopting a streamlined brand identity while maintaining the same formulations, manufacturing standards, team, and commitment to quality its customers have trusted for more than a decade.

“NCL represents the quality, transparency, and innovation that our community expects from us. As we enter this new chapter, our commitment to our customers and our standards remains as strong as ever.”

NCL stands for Natural Cure Labs. The name change reflects how customers and the team already refer to the company. Over the past 10+ years, “NCL” has become the natural shorthand for Natural Cure Labs – and this transition formalizes that identity. This is a name change and visual evolution only. Ownership, leadership, formulations, and values remain unchanged.

Same Mission, Sharper Identity

This transition is not a departure from who the company is – it is a natural progression. The values that have guided NCL from the very beginning remain unchanged: clean-label quality, third-party testing, science-backed formulations, and an unwavering commitment to transparency. What is changing is how the company presents itself. In the months ahead, this rebrand will be accompanied by further updates across the brand experience – from visual identity and packaging to how NCL shows up across every channel and platform. Each of these changes will reflect the same standard of excellence customers have come to expect.

What is changing is how the company presents itself. In the months ahead, this rebrand will be accompanied by further updates across the brand experience – from visual identity and packaging to how NCL shows up across every channel and platform. Each of these changes will reflect the same standard of excellence customers have come to expect.

More Than 10 Years of Trust

This evolution comes at a time of significant momentum. Since 2015, NCL has grown from a small startup into an award-winning wellness brand available nationwide through Amazon, Walmart, Target+, TikTok Shop, eBay, and other major marketplaces. Along the way, the company has reached milestones that reflect the trust its community has placed in it:

200,000+ customers served worldwide35+ million capsules sold7,000+ verified customer reviewsRecognition in the 2025 Inc. 5000 list of fastest-growing private companiesMultiple Stevie Awards from the American Business AwardsNamed a 2025 and 2026 Gator100 HonoreeThree-time Global 100 winner for Best Health & Wellness Nutrition Manufacturer

“This rebrand isn’t about changing who we are – it’s about evolving how we present ourselves to match the brand our customers already know and trust,” said Damon Sununtnasuk, Founder & CEO.

What This Means for Customers

For existing customers, nothing changes about the products they know and trust. The same formulations, manufacturing facilities, quality controls, and customer support team remain in place. Products sold as Natural Cure Labs and products sold as NCL are from the same company. Customers can continue to find NCL products on the company’s website and through Amazon, Walmart, Target+, Kroger, eBay, and other major marketplaces.

NCL is grateful for every customer who has been part of this journey and is excited for what is to come.

Media Contact

NCL (Natural Cure Labs), NCL (Natural Cure Labs), 1 8003036214, press@naturalcurelabs.com, https://www.naturalcurelabs.com/

View original content to download multimedia:https://www.prweb.com/releases/ncl-formerly-natural-cure-labs-unveils-new-brand-identity-reinforcing-its-position-as-a-leading-monolaurin-supplement-company-302753477.html

SOURCE NCL (Natural Cure Labs)

Continue Reading

Technology

DJI Launches Beginner-Friendly Camera Drone Series with Lito X1 and Lito 1

Published

on

By

Creators now have an accessible option for filming high-quality aerial photography while flying safely with omnidirectional obstacle sensing.

SHENZHEN, China, April 26, 2026 /PRNewswire/ — DJI, the global leader in civilian drones and creative camera technology, today launches the Lito series. Designed for aspiring creators exploring aerial photography for the first time, this new lineup of entry-level aerial camera drones makes high-altitude aerial photography accessible and beginner-friendly from day one. With its affordable price point and well-rounded features, the Lito X1 and Lito 1 strike the perfect balance between high performance and value. It’s an ideal camera drone for young newcomers to aerial photography who want to capture campus life, outdoor adventures, and creative moments without compromise.

Leading the range, the premium Lito X1 features a 1/1.3″ CMOS sensor with 48MP effective pixels for lifelike detail capture. It’s equipped with advanced 5-lux omnidirectional obstacle sensing and forward-facing LiDAR for enhanced precision—ensuring safer flight in complex environments. The intelligent filming tools, such as ActiveTrack, QuickShots, MasterShots, Hyperlapse, and Panorama, lower the learning curve and ensure professional results from a creator’s first takeoff. Meanwhile, the Lito 1 offers a 1/2″ CMOS 48MP sensor and comprehensive 5-lux omnidirectional obstacle sensing, bringing safety and tracking capabilities to an even more accessible package.

Smarter Sensing for Safer Flying

The Lito Series features a multi-layered safety system designed with beginners in mind. The built-in omnidirectional vision system actively avoids obstacles like cliffs, and walls, allowing creators to focus on the joy of flying from takeoff to landing. The premium Lito X1 takes this a step further, enhanced with forward-facing LiDAR for highly precise perception in complex environments.

Captures Crisp Imaging, Rich in Detail

The Lito Series makes it possible to capture stunning visuals – from rich daytime details to clean, low-noise nightscapes. Lito 1 is equipped with a 1/2-inch CMOS sensor and an f/1.8 aperture to capture up to 8K-resolution photos and 4K-resolution video, retaining crisp detail even when zoomed or cropped. The premium Lito X1 uplevels the camera with a 1/1.3-inch CMOS sensor and an f/1.7 aperture, supporting HDR video recordings with up to 14 stops of dynamic range and 10-Bit D-Log M. 

Get High-Quality Shots with ActiveTrack and Smart Modes

The Lito Series delivers stable subject tracking via ActiveTrack, even at speeds up to 12 m/s. Combined with QuickShots, MasterShots, Hyperlapse, and Panorama modes, beginners can automatically execute complex camera moves and capture high-quality footage with ease.

Fly Farther with a Stable View

The Lito Series offers up to 36 minutes of flight time with the standard Intelligent Flight Battery. It also features wind resistance up to 10.7 m/s, allowing the camera drone to hover and fly stably in windy conditions.

Create with Ease and Efficiency

With QuickTransfer, files can be transferred up to 50 MB/s via Wi-Fi 6. Additionally, the premium Lito X1 includes 42GB of internal storage.

Price and Availability

DJI Lito 1 and DJI Lito X1 are available for order starting today through store.dji.com and authorized retailers. Pricing and configurations are as follows: 

DJI Lito 1

DJI Lito 1 retails for 339 EURDJI Lito 1 Fly More Combo (DJI RC-N3) retails for 479 EUR

DJI Lito X1

DJI Lito X1 retails for 419 EURDJI Lito X1 Fly More Combo (DJI RC 2) retails for 579 EUR

DJI Care Refresh

DJI Care Refresh, the comprehensive protection plan for DJI products, is now available for DJI Lito 1. The replacement service covers accidental damage, including flyaway, collisions and water damage. For a small additional charge, you can have your damaged product replaced if an accident occurs.

DJI Care Refresh (1-Year Plan) includes up to two replacements in one year. DJI Care Refresh (2-Year Plan) includes up to four replacements in two years. Other services of DJI Care Refresh include official Warranty and free shipping. For a full list of details, please visit: https://www.dji.com/support/service/djicare-refresh

For more information, please refer to:
https://www.dji.com/lito-x1
https://www.dji.com/lito-1

1 All data was measured using a production model of the DJI Lito 1 and DJI Lito X1 in a controlled environment; actual experience may vary. For more information, please refer to https://www.dji.com/lito-x1 and https://www.dji.com/lito-1

.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/dji-launches-beginner-friendly-camera-drone-series-with-lito-x1-and-lito-1-302753608.html

SOURCE DJI

Continue Reading

Technology

Silicon Valley Stars Gather for Dreame’s San Francisco Debut

Published

on

By

SAN FRANCISCO, April 25, 2026 /PRNewswire/ — Dreame Technology, a global high-end technology company, confirmed the guest lineup for DREAME NEXT, the company’s largest-ever international launch event, running April 27 to 30, 2026, in San Francisco. The roster brings together figures who have shaped the trajectory of autonomous driving, personal computing, and professional sports: Sebastian Thrun, Steve Wozniak, and Dwyane Wade will all attend.

The breadth of expertise on the guest list reflects the reach of DREAME NEXT itself. Over four days, Dreame will stage product launches across smart mobility, smart home appliances, personal devices, and premium personal care, the first time a single event from the company has spanned its full product ecosystem. The event is organized around five themed segments: Drive Next, Living Next, Connect Next, Self Next, and Humanity Next.

Over the course of the four-day launch event, DREAME NEXT will bring together leading voices from across technology, academia, investment, and innovation to explore the next stage of industry transformation. Discussions will center on how AI-driven applications are reshaping products from the ground up, whether the age of AI requires products to be fundamentally reimagined, how intelligent technologies will redefine the foundations of manufacturing productivity, and what the next decade of human technological evolution may look like.

Featured speakers include AI pioneer Sebastian Thrun (Google X, Udacity), tech futurist Robert Scoble (Microsoft), Meta design leader Julie Zhuo, AI strategist William Fong (Microsoft), and business veteran James W. Keyes (7-Eleven, Blockbuster). The lineup also features Turing Award winner David Patterson, NASA rocket scientist Sylvia Acevedo, Stanford GSB’s Yossi Feinberg, economist Barry Eichengreen, tech journalist Rebecca A. Fannin, engineering leader Jim Chen, and Fremont Mayor Emeritus Lily Mei, alongside former Google DeepMind AI researchers and the co-founders of Robot Launch. These global leaders will share insights on AI, technology, innovation, economics, and entrepreneurship.

Demonstrating Dreame’s growing global influence, the event will also welcome standout guests from beyond the technology sector, including Apple co-founder and personal computing pioneer Steve Wozniak; and three-time NBA champion Dwyane Wade.

The guests in attendance at DREAME NEXT reflect where the company is headed; that leaders from autonomous driving, personal computing, and professional sports are all in the same room for a single company’s launch event speaks to the scale and ambition of what Dreame is building. DREAME NEXT is not just a product launch but the opening chapter of the company’s next ten years.

Dreame’s product portfolio now spans categories that, until recently, belonged to entirely separate industries. DREAME NEXT is designed to demonstrate that these categories are connected by core technologies, including high-speed motors, intelligent algorithms, and bionic robotic arms, which are now being applied across smart mobility, personal devices, home appliances, and personal care. It represents not only the next generation of products and lifestyles, but also the beginning of Dreame’s vision for the next decade.

DREAME NEXT runs April 27 to 30, 2026, in San Francisco. Media, partners, and invited guests are welcome to attend.

Please stay tuned for the latest updates from the event through the official website or the social accounts on X: @DreameGlobal, Facebook: Dreame Tech, and Instagram: @dreame_tech.

About Dreame Technology

Founded in 2017, Dreame Technology is a global high-end technology brand built on a foundation of high-speed digital motors, intelligent algorithms, and bionic robotic arms. The company’s product portfolio spans smartphones, smart vehicles, smart home appliances, intelligent cleaning appliances, outdoor smart devices, and personal care, designed to simplify daily life and give users more time for what matters. Dreame operates in more than 120 countries and regions with over 6,500 offline stores and serves more than 42 million households globally. As of December 31, 2025, the company has filed more than 10,000 patents worldwide and holds over 3,000 granted patents.

View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-valley-stars-gather-for-dreames-san-francisco-debut-302753481.html

SOURCE Dreame Technology

Continue Reading

Trending